Literature DB >> 30202088

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Roger D Kouyos1,2, Peter Rusert3, Claus Kadelka3,4, Michael Huber3, Alex Marzel3,4, Hanna Ebner3, Merle Schanz3, Thomas Liechti3,5, Nikolas Friedrich3, Dominique L Braun3,4, Alexandra U Scherrer3,4, Jacqueline Weber3, Therese Uhr3, Nicolas S Baumann3, Christine Leemann3,4, Herbert Kuster3,4, Jean-Philippe Chave6, Matthias Cavassini7, Enos Bernasconi8, Matthias Hoffmann9, Alexandra Calmy10, Manuel Battegay11, Andri Rauch12, Sabine Yerly13, Vincent Aubert14, Thomas Klimkait15, Jürg Böni3, Karin J Metzner3,4, Huldrych F Günthard16,17, Alexandra Trkola18.   

Abstract

Understanding the determinants of broadly neutralizing antibody (bNAb) evolution is crucial for the development of bNAb-based HIV vaccines1. Despite emerging information on cofactors that promote bNAb evolution in natural HIV-1 infections, in which the induction of bNAbs is genuinely rare2, information on the impact of the infecting virus strain on determining the breadth and specificity of the antibody responses to HIV-1 is lacking. Here we analyse the influence of viral antigens in shaping antibody responses in humans. We call the ability of a virus strain to induce similar antibody responses across different hosts its antibody-imprinting capacity, which from an evolutionary biology perspective corresponds to the viral heritability of the antibody responses. Analysis of 53 measured parameters of HIV-1-binding and neutralizing antibody responses in a cohort of 303 HIV-1 transmission pairs (individuals who harboured highly related HIV-1 strains and were putative direct transmission partners or members of an HIV-1 transmission chain) revealed that the effect of the infecting virus on the outcome of the bNAb response is moderate in magnitude but highly significant. We introduce the concept of bNAb-imprinting viruses and provide evidence for the existence of such viruses in a systematic screening of our cohort. The bNAb-imprinting capacity can be substantial, as indicated by a transmission pair with highly similar HIV-1 antibody responses and strong bNAb activity. Identification of viruses that have bNAb-imprinting capacities and their characterization may thus provide the potential to develop lead immunogens.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30202088     DOI: 10.1038/s41586-018-0517-0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  17 in total

1.  Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.

Authors:  Bongiwe Ndlovu; Kamini Gounder; Daniel Muema; Nagarajan Raju; Tandile Hermanus; Qiniso Mthethwa; Kim Robertson; Bruce D Walker; Ivelin S Georgiev; Lynn Morris; Penny L Moore; Thumbi Ndung'u
Journal:  Virology       Date:  2020-03-25       Impact factor: 3.616

Review 2.  The antibody response in HIV-1-infected donors.

Authors:  Simone I Richardson; Penny L Moore
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

3.  Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins.

Authors:  Nitesh Mishra; Muzamil Ashraf Makhdoomi; Shaifali Sharma; Sanjeev Kumar; Ayushman Dobhal; Deepshikha Kumar; Himanshi Chawla; Ravinder Singh; Uma Kanga; Bimal Kumar Das; Rakesh Lodha; Sushil K Kabra; Kalpana Luthra
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

4.  A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.

Authors:  Sarah Welbourn; Srirupa Chakraborty; Jie E Yang; Anne S Gleinich; Sailaja Gangadhara; Salar Khan; Courtney Ferrebee; Bhrugu Yagnik; Samantha Burton; Tysheena Charles; S Abigail Smith; Danielle Williams; Rohini Mopuri; Amit A Upadhyay; Justin Thompson; Matt A Price; Shiyu Wang; Zhaohui Qin; Xiaoying Shen; LaTonya D Williams; Nathan Eisel; Tiffany Peters; Lu Zhang; William Kilembe; Etienne Karita; Georgia D Tomaras; Steven E Bosinger; Rama R Amara; Parastoo Azadi; Elizabeth R Wright; Sandrasegaram Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2022-05-03       Impact factor: 6.823

5.  B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.

Authors:  Samantha M Townsley; Gina C Donofrio; Ningbo Jian; David J Leggat; Vincent Dussupt; Letzibeth Mendez-Rivera; Leigh Anne Eller; Lauryn Cofer; Misook Choe; Philip K Ehrenberg; Aviva Geretz; Syna Gift; Rebecca Grande; Anna Lee; Caroline Peterson; Mary Bryson Piechowiak; Bonnie M Slike; Ursula Tran; M Gordon Joyce; Ivelin S Georgiev; Morgane Rolland; Rasmi Thomas; Sodsai Tovanabutra; Nicole A Doria-Rose; Victoria R Polonis; John R Mascola; Adrian B McDermott; Nelson L Michael; Merlin L Robb; Shelly J Krebs
Journal:  Cell Host Microbe       Date:  2021-03-03       Impact factor: 21.023

6.  Immune Correlates of Disease Progression in Linked HIV-1 Infection.

Authors:  Michael Tuen; Jude S Bimela; Andrew N Banin; Shilei Ding; Gordon W Harkins; Svenja Weiss; Vincenza Itri; Allison R Durham; Stephen F Porcella; Sonal Soni; Luzia Mayr; Josephine Meli; Judith N Torimiro; Marcel Tongo; Xiaohong Wang; Xiang-Peng Kong; Arthur Nádas; Daniel E Kaufmann; Zabrina L Brumme; Aubin J Nanfack; Thomas C Quinn; Susan Zolla-Pazner; Andrew D Redd; Andrés Finzi; Miroslaw K Gorny; Phillipe N Nyambi; Ralf Duerr
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

7.  Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies.

Authors:  Panpan Zhou; Han Wang; Mengqi Fang; Yangyang Li; Hua Wang; Shasha Shi; Zihao Li; Jiapeng Wu; Xiaoxu Han; Xuanling Shi; Hong Shang; Tongqing Zhou; Linqi Zhang
Journal:  PLoS Pathog       Date:  2019-06-13       Impact factor: 6.823

Review 8.  Impact of HIV-1 Diversity on Its Sensitivity to Neutralization.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Martine Braibant; Francis Barin
Journal:  Vaccines (Basel)       Date:  2019-07-25

9.  Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains.

Authors:  Andrew D Redd; Nicole A Doria-Rose; Joshua A Weiner; Martha Nason; Matthew Seivers; Stephen D Schmidt; Oliver Laeyendecker; Craig Martens; Daniel Bruno; Brandon F Keele; Nagarajan Raju; Ivelin S Georgiev; Susanna L Lamers; Jacquie Astemborski; Gregory D Kirk; John R Mascola; Margaret E Ackerman; Shruti H Mehta; Thomas C Quinn
Journal:  J Infect Dis       Date:  2020-02-18       Impact factor: 7.759

10.  Bringing the path toward an HIV-1 vaccine into focus.

Authors:  Cesar J Lopez Angel; Georgia D Tomaras
Journal:  PLoS Pathog       Date:  2020-09-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.